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Chemokines are peptide mediators involved in normal development, hematopoietic and immune regulation, wound healing,
and inﬂammation. Among the chemokines is CXCL12, which binds principally to its receptor CXCR4 and regulates leukocyte
precursor homing to bone marrow and other sites. This role of CXCL12/CXCR4 is “commandeered” by cancer cells to facilitate
the spread of CXCR4-bearing tumor cells to tissues with high CXCL12 concentrations. High CXCR4 expression by cancer
cells predisposes to aggressive spread and metastasis and ultimately to poor patient outcomes. As well as being useful as a
marker for disease progression, CXCR4 is a potential target for anticancer therapies. It is possible to interfere directly with
the CXCL12:CXCR4 axis using peptide or small-molecular-weight antagonists. A further opportunity is oﬀered by promoting
strategies that downregulate CXCR4 pathways: CXCR4 expression in the tumor microenvironment is modulated by factors such
as hypoxia, nucleosides, and eicosanoids. Another promising approach is through targeting PPAR to suppress CXCR4 expression.
EndogenousPPARγ suchas15-deoxy-Δ12,14-PGJ2 andsyntheticagonistssuchasthethiazolidinedionesbothcausedownregulation
of CXCR4 mRNA and receptor. Adjuvant therapy using PPARγ agonists may, by stimulating PPARγ-dependent downregulation
of CXCR4 on cancer cells, slow the rate of metastasis and impact beneﬁcially on disease progression.
Copyright © 2008 C. L. Richard and J. Blay. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
The regulation of the distribution of motile cells in both
normal and disease situations depends upon a variety of
peptide and nonpeptide mediators, which stimulate cell
movement by both directed (chemotaxis) and nondirected
(chemokinesis) mechanisms. Amongst these mediators are
the chemokines, a class of peptide mediators that play
critical roles in normal development, regulation of the
hematopoietic and immune systems in the adult, and in
repair processes such as wound healing and inﬂammation.
Among the diﬀerent chemokines is the stromal cell-derived
factor-1 (SDF-1), which is now known as CXCL12. CXCL12
bindsprincipallytothereceptorCXCR4,althoughitalsoacts
through the more-recently-described receptor CXCR7 [1].
This review describes the roles of CXCL12 and CXCR4 in
normal tissue functions and in cancer, and suggests that the
regulation of CXCR4 expression by PPARγ may emerge to be
a unique avenue by which a key receptor involved in cancer
cell metastasis can be suppressed in a way that will assist with
disease therapy.
2. CHEMOKINES AND THEIR RECEPTORS IN
CELL REGULATION
Chemokines are low-molecular-weight peptide ligands
involved in the traﬃcking of leukocytes and other motile
cells [2, 3]. There are four major groups of chemokines,
the CXC, CC, C and CX3C chemokines, categorized as such
on the basis of their number and spacing of conserved
cysteine residues [2, 4]. The nomenclature of chemokines
(e.g.,“CXCL12”)ismadeupoftheirsubclass(CXC,CC,etc.)
followed by “L” for ligand, and a speciﬁc number [2, 3].
The receptors for chemokines are cell-surface, seven-
transmembrane G protein-coupled receptors [2]. The nam-
ing of these receptors (e.g., “CXCR4”) is based on the sub-
class of chemokine that the receptor recognizes, followed by
“R” for receptor and a number (which need not correspond2 PPAR Research
to the number assigned to its cognate ligand(s)). There
are 19 well-recognized chemokine receptors (e.g., CXCR1-
6, CCR1-10, CX3CR1, and XCR1) [1, 5]. Many chemokine
receptors have more than one known ligand, and many
chemokines can activate more than one receptor. Thus, there
is much promiscuity in chemokine/receptor signaling.
Chemokines bind within the extracellular domain of
the chemokine receptor, which comprises the N-terminus
and three extracellular loops [3]. The intracellular domain,
which consists of three loops and the C-terminus, associates
with G proteins that, upon activation, lead to inhibition
of adenylyl cyclase activity [3]. Typical cellular conse-
quences of chemokine binding include changes in gene
expression, cell polarization, and chemotaxis (directed cell
migration) [4].
Chemokinesplayamajorroleinregulatingthemigration
of cells of the immune system, leading to the modulation of
immune responses. Their exact role depends on the expres-
sion pattern of receptors on speciﬁc leukocyte subsets [2]
but encompasses the regulation of lymphocyte traﬃcking,
lymphoid tissue development, Th1/Th2 modulation, and the
eﬀecting of inﬂammatory reactions. Chemokine receptors
are also found on other cell types, and play a part in stem cell
recruitment and angiogenesis, in development and wound
healing [4]. When such pathways are subverted in neoplastic
cells, chemokines take over prominent roles in the metastatic
process, both in terms of the dissemination of cells from
primary tumors and in growth of the cancer at metastatic
sites. As we will see, this is the case for CXCR4.
3. THE CHEMOKINE RECEPTOR CXCR4 AND
ITS LIGAND CXCL12 (SDF-1)
The receptor now known as CXCR4 was cloned in 1994,
and was originally given the name leukocyte-expressed
seven-transmembrane domain receptor (LESTR) due to its
abundant expression in several leukocyte populations [6].
It was independently cloned by others and named “fusin”
because of its ability to act as a coreceptor for HIV fusion
and entry [7]. It further has the designation “CD184” as part
of the cluster of diﬀerentiation antigens found on activated
leukocytes. LESTR/fusin/CD184 was originally considered to
be an orphan receptor. However, the chemokine CXCL12,
originally termed stromal cell-derived factor 1 (SDF-1), was
shown by two independent research groups to be a ligand for
LESTR/fusin/CD184,andthenameCXCR4wasproposed[8,
9]. The CXCR4 gene is constitutively expressed, and CXCR4
protein has been detected on many leukocytes, including
lymphocytes, monocytes, NK cells, and dendritic cells; as
well as on vascular smooth muscle cells, endothelial cells,
cells lining the gastrointestinal tract, microglia, neurons, and
astrocytes [10–13]. Until recently, CXCR4 was considered to
be the only receptor for CXCL12, but the previous orphan
receptor RDC1 is now recognized as an additional CXCL12
receptor, for which the name CXCR7 has been given [1].
CXCL12 itself is widely expressed at diﬀerent levels in many
tissues [14].
4. CXCL12ANDCXCR4INNORMALTISSUEFUNCTION
The interplay between CXCL12 and CXCR4 is critical to
normal development. Indeed (and unlike mice deﬁcient
in other chemokine/receptors) mice lacking CXCL12 or
CXCR4 die in utero or shortly after birth [2, 15–17].
CXCL12/CXCR4 signaling is required during the develop-
ment of the hematopoietic, cardiac, vascular, and nervous
systems. Absence of this axis in embryonic life leads to
defects in bone marrow myeloid cell formation, cardiac
dysfunction due to impaired ventricular septum formation,
and developmental defects in the cerebellum and in the
vasculature of the gastrointestinal tract [15–17].
In the normal adult, CXCL12 and CXCR4 are involved
in the homing and retention of hematopoietic progenitor
cells in the bone marrow. These progenitor cells express high
levels of CXCR4, and are attracted to CXCL12 produced
by stromal cells in specialized bone marrow niches [18].
Activating mutations of the CXCR4 gene lead to aberrant
retention of myeloid cells within the bone marrow [19].
CXCL12 also acts as a chemoattractant for stem cells and
some diﬀerentiated cells in the pathological contexts of
inﬂammation and tissue regeneration/repair [20–24]. It is
this function of controlling cell migration and homing that
is subverted in cancer.
5. CXCL12 AND CXCR4 IN CANCER
METASTASIS AND GROWTH
In many ways, the process of metastasis is similar to leuko-
cyte and stem cell traﬃcking, processes which involve the
CXCL12/CXCR4 axis [20]. Cancer cells that express CXCR4
exploit the same signaling pathway, leading to homing and
retention in tissues that are rich in CXCL12.
The foundation for our appreciation of the role that
CXCR4 and CXCL12 may play in cancer metastasis was set
in 2001, when a landmark study by Albert Zlotnik’s group
demonstrated the importance of the CXCL12/CXCR4 axis in
site-speciﬁc metastasis of breast cancer [25]. In that study, it
wasfoundthatCXCR4expressionwasloworundetectablein
normal epithelial cells, but consistently upregulated in breast
cancer cell lines and primary breast cancer cells at both the
mRNA and protein level. Human breast carcinoma cells that
expressed high levels of CXCR4 underwent morphological
changes and migrated directionally in response to CXCL12,
indicating that the CXCR4 receptor was active. Crucially, the
ligand CXCL12 was highly expressed in tissues taken from
human organ sites to which breast cancer cells metastasize,
including lymph nodes, lung, liver, and bone marrow, but
expressed at low levels in tissues that represent rare sites
of metastasis, including the kidney, skin, and muscle. The
ability of MDA-MB-231 human breast cancer cells (a cell
line that is metastastic in experimental models) to migrate
towards protein extracts of lung and liver, or to produce
lung and lymph node metastasis after tail-vein injection
or orthotopic implantation, was inhibited by neutralizing
anti-CXCR4 and/or anti-CXCL12 antibodies. These ﬁndings
were the ﬁrst to show the biological importance of thisC. L. Richard and J. Blay 3
chemokine/receptor pair in the evolution and spread of
cancer.
Sincethattime,theCXCL12/CXCR4axishasbeenshown
to be important in the progression and spread of more
than 25 diﬀerent cancers. Our present knowledge is based
on (i) studies in cellular and animal experimental models,
(ii) surveys of human tissues at diﬀerent stages of cancer
progression, and (iii) population-based studies of morbidity
and survival. A summary of present data is shown in Table 1.
CXCR4 has been shown to be expressed at high levels on
cells of all of the major adult solid epithelial cancers (breast,
colorectal, lung, ovary, prostate, etc.). The ability of the cells
to colonize other tissues by gaining advantage from CXCR4-
dependent mechanisms depends on the presence of CXCL12
in the tissue ﬂuid. Various studies have shown signiﬁcant
CXCL12 concentrations in the ﬂuid-ﬁlled cavities through
which many cancers disseminate, and at tissue locations
in which metastases characteristically develop. Biologically,
signiﬁcant CXCL12 levels have been found in peritoneal
ascites from ovarian cancer patients [26], pleural eﬀusions
in lung cancer [27], lymph nodes, bone, and lungs as well as
other tissues [25, 28, 29].
Detailed studies of the cellular interactions involved in
the metastasis of prostate cancer cells to bone [29]h a v e
shown that the interaction of CXCL12 with CXCR4 plays
a major role in successive steps in the metastatic process.
Human osteoblasts express CXCL12 mRNA and protein,
whereas prostate cancer cells express CXCR4 mRNA and
receptor.Prostatecancercellsthathavebecomedisseminated
into the circulation respond to the CXCL12-CXCR4 pathway
by enhanced adherence to the bone marrow endothelium
and migration across endothelial barriers and basement
membranes, ultimately adhering to components of the bone
marrow in response to a CXCL12 gradient [29]. CXCL12
from osteoblasts has also been shown to act on CXCR4 to
induce release of IL-6 from human squamous cell carcinoma
cells to promote osteoclastogenesis [30].
As well as promoting the migration of cancer cells and
their invasion through physical barriers as well as adherence
to target structures, CXCL12 can act upon CXCR4 on
the cancer cells to promote cancer cell growth along with
other mitogenic factors. This has been shown in cells from
colorectal [31], prostate [32], and ovarian [33]c a n c e r s .
Furthermore, CXCL12 can promote cancer dissemination
indirectly by enhancing the vascular supply, since the
CXCL12/CXCR4 axis may also promote tumor angiogenesis.
Vascular endothelial growth factor (VEGF) and CXCL12
have been shown to increase angiogenesis synergistically
in an in vivo Matrigel assay and to promote proliferation
and migration of human umbilical vein endothelial cells
(HUVECs) in vitro [34].
6. THE EFFECT OF CXCL12 ON CELLULAR PROCESSES
Activation of CXCR4 produces speciﬁc cellular changes that
are consistent with a migratory and invasive cell phenotype.
Exposure of cells to CXCL12 produces upregulation of
matrix metalloproteinases (MMPs) such as MMP-2 and
MMP-9 [25, 26, 29, 35–39]. In addition, CXCL12 enhances
adhesion to components of the extracellular matrix such as
ﬁbronectin, laminin, and collagen types I/III [37, 40], or to
other cell types (e.g., endothelial or bone marrow stromal
cells) [29, 41, 42]. These changes are mediated in large part
by integrin signaling [29, 43, 44]. Many signaling pathways
are activated by CXCL12 downstream of CXCR4 in cancer
cells. For example, CXCL12 has been shown to increase
ERK1/2 phosphorylation [30,31,49,0.70,76.78,79], Akt
phosphorylation [50,77.88], and PI3K activation [45].
7. CXCR4 IN BREAST CANCER
CXCR4 is expressed at a low level in normal breast
epithelium but becomes more strongly expressed in the
early stages of carcinogenesis, showing both a more intense
immunohistochemical staining pattern and an altered cel-
lular localization in studies of human ductal carcinoma in
situ (DCIS) [46, 47]. An extensive tissue microarray study of
1808 invasive breast carcinomas and 214 pre-invasive breast
samples linked to clinical data has shown that the level
of CXCR4 expression can be linked to tumor progressivity
(tumor grade and lymph node status) and to other prognos-
tic factors such as HER2 expression and hormone receptor
(ER and PR) negativity, as well as to patient survival [46].
T h e s eo b s e r v a t i o n si nh u m a nt i s s u e sh a v el e dt ot h ev i e w
that CXCR4 provides a selective advantage to newly formed
neoplastic cells in the early primary breast tumor as well as
being important to later invasion and metastasis [13, 46–
48]. This is consistent with observations in mouse models
of breast cancer in which interventions aﬀecting CXCR4
reduced both growth of the primary tumor and metastasis
[49].
Prominent CXCR4 expression is a feature of all major
histological forms of invasive breast cancer, including ductal,
lobular, mucinous [46], and the distinctive and highly
aggressive inﬂammatory form of the disease [50]. Several
independent studies have shown that the extent and pattern
of CXCR4 expression is related to axillary lymph node
involvement in diﬀerent forms and stages of breast cancer
[28, 51–53]. CXCR4 positivity has also been noted as a key
feature of breast carcinoma metastasis to bone [54]a n d
brain [55]. The power of CXCR4 as a marker for lymph
node metastasis can be greatly increased by concurrently
examining the expression of additional markers such as
VEGF, MMP-9, and CCR7 [38, 56]. Furthermore, CXCR4 is
alsooneofasubsetofmarkers(theothersareuPAR,S100A4,
and vimentin) that deﬁne highly aggressive and invasive
breast carcinoma cells that are associated with malignant
pleural or peritoneal eﬀusions in breast cancer patients
[57]. CXCR4 expression is therefore a general marker for
the spread of breast cancer to its secondary sites, and for
aggressive stages of the disease.
T h e r ei se v i d e n c en o to n l yf o rt h eu s eo fC X C R 4a s
a general marker for the progression and metastasis of
breast cancer, but also for the identiﬁcation of individual
tumor cells as they are homing from the primary tumor
to secondary sites as patients develop metastatic disease.
Individual CXCR4-expressing tumor cells have been found4 PPAR Research
Table 1: Involvement of CXCL12/CXCR4 in diﬀerent cancers.
Cancer Comments References
Acute lymphoblastic
leukemia
Levels of CXCR4 are elevated on lymphoblasts. Elevated levels
of CXCR4 are associated with increased inﬁltration in liver and
spleen
[58]
Acute myelogenous
leukemia
High CXCR4 expression is associated with relapse and reduced
survival
[59]
Brain cancer
CXCR4 expression is demonstrated in tissues and cell lines
derived from glioblastoma, medulloblastoma, and astrocytoma.
Cell lines respond to CXCL12 with increased proliferation, sur-
vival and migration. Gliomas expressing CXCR4 are associated
with increased tumor size and reduced survival
[41, 60–64]
Breast cancer
High CXCR4 expression is noted in breast cancer tissues
compared to normal tissues and cell lines with invasive char-
acteristics. CXCR4 expression is associated with more extensive
lymph node metastasis and with liver metastasis, although
CXCR4 expression in lymph node metastases may be lower than
primary cancers. CXCR4 co-expression with HER2/neu is an
indicator of more extensive lymph node involvement
[25, 28, 65–67]
Cervical cancer CXCR4 expression is associated with increased tumor size,
stromal invasion, lymph node metastasis, and reduced survival
[68]
Chronic lymphocytic
leukemia
Malignant B cells express 3- to 4-fold higher cell-surface CXCR4
levels than normal B cells. High CXCR4 expression on B cells is
associatedwithreducedsurvivalinpatientswithfamilialchronic
lymphocytic leukemia
[69, 70]
Colorectal cancer
CXCR4 is over-expressed in colorectal carcinoma tissues com-
pared to normal tissues, and on certain established cell lines.
In patients with liver metastasis, higher CXCR4 expression is
found on liver metastases compared to the primary tumor. In
patients with stage I/II disease, high CXCR4 mRNA expression
intumorsamplesisassociatedwithincreaseddiseaserecurrence.
In patients with stage IV disease, patients with high CXCR4 have
decreased overall survival. High CXCR4 expression is associated
with increased lymph node involvement and distant metastasis,
as well as reduced 3-year survival
[40, 71–75]
Endometrial cancer
Endometrial adenocarcinoma tissues and human cell lines
express CXCR4 protein. CXCL12 induces proliferation of
endometrial carcinoma cells
[76]
Esophageal cancer CXCR4 expression is associated with reduced survival and
increased lymph node/bone marrow metastasis
[77]
Gastric cancer
A majority of primary gastric tumors and many human
gastric carcinoma cell lines express CXCR4. Primary tumors
that express CXCR4 protein are associated with peritoneal
carcinomatosis
[78]
Head and neck squa-
mous cell cancer
CXCR4expressionisfoundintissuesandcelllines.HighCXCR4
expression is associated with increased occurrence of distant
metastases and reduced survival
[79, 80]
Hepatocellular
carcinoma
CXCR4 is correlated with tumor progression, metastasis, and
reduced survival
[81]
Melanoma
CXCR4 protein is expressed on human melanoma cell lines,
as well as on cells isolated from melanoma surgical specimens.
CXCL12 enhances cell adhesion to ﬁbronectin, the binding of
murine melanoma cells to endothelial cells, and invasion of
human melanoma cells across basement membranes. CXCR4
expression is associated with reduced disease-free survival and
overall survival
[35, 43, 82, 83]
Multiple myeloma
Multiple myeloma cells isolated from bone marrow and multiple
myeloma cell lines express cell-surface CXCR4 protein. CXCL12
enhances adhesion to ﬁbronectin and stimulates cell migration
[84]C. L. Richard and J. Blay 5
Table 1: Continued.
Cancer Comments References
Nasopharyngeal
cancer
Mostprimaryhumannasopharyngealcarcinomabiopsysamples
and metastatic lymph nodes stain positively for CXCR4 protein.
Nasopharyngeal carcinoma cell lines also express CXCR4 mRNA
[85]
Non-Hodgkin’s
lymphoma
Most tissue samples and cell lines express high levels of
CXCR4 mRNA and cell-surface protein. CXCR4 is implicated in
transendothelial migration and proliferation of non-Hodgkin’s
lymphoma cells
[86]
Nonmelanoma skin
cancer
CXCR4 is expressed on invasive squamous cell carcinoma and
basal cell carcinoma tissues. Expression on invasive squamous
cell carcinoma is increased compared to normal skin
[87]
Non-small cell lung
cancer
CXCR4 mRNA is upregulated in NSCLC tissues compared to
normaltissues,andlevelsarehigherintissuesamplestakenfrom
patients with metastasis than from those without metastasis.
Overexpression of CXCR4 in NSCLC cells leads to enhanced
migratory, invasive, and adhesive responses to CXCL12. Nuclear
CXCR4 staining is associated with longer survival and reduced
incidence of metastasis
[88, 89]
Osteosarcoma
CXCR4 mRNA is expressed in most human osteosarcoma
samples, and two of three osteosarcoma cell lines. CXCR4
expressionishigheratmetastaticsitesthanintheprimarytumor
[90, 91]
Ovarian cancer
CXCR4 mRNA is expressed in ovarian cancer cell lines, as well
as in biopsies from primary tumors and ovarian cancer ascites.
High levels of CXCL12 are present in ascitic ﬂuid taken from
patients with ovarian cancer. CXCL12 stimulates the growth
of ovarian cancer cells. CXCR4 expression is associated with
increased recurrence and reduced survival
[26, 33, 92]
Pancreatic cancer
Most human pancreatic cancer tissues stain positively for
CXCR4 expression, and more than half of pancreatic cancer cell
lines express CXCR4 mRNA and cell-surface protein. CXCL12
induces chemotaxis of human pancreatic carcinoma cells, as well
as stimulates proliferation and promoted survival
[42, 93]
Prostate cancer
ProstatecancercelllinesexpressCXCR4mRNAandprotein,and
approximately half of prostate cancer tissues stain positively for
CXCR4. Treatment of cells with CXCL12 increases their adher-
ence to osteosarcoma cells and bone marrow endothelial cells,
transendothelial migration, and invasion into Matrigel. CXCR4
expression is a positive predictor of bone metastasis, particularly
in patients with elevated prostate speciﬁc antigen (PSA) levels.
High CXCR4 expression is associated with increased cancer-
speciﬁc mortality
[29, 36, 94, 95]
R e n a lc e l lc a n c e r
One of four human renal cell cancer lines express CXCR4
mRNA, which is upregulated in renal cell cancer tumor samples
compared to normal tissue. High CXCR4 expression is associ-
ated with poor tumor-speciﬁc survival, independent of tumour
stage and diﬀerentiation grade
[96, 97]
Rhabdomyo sarcoma
Severalrhabdomyosarcomacelllinesexpresscell-surfaceCXCR4
protein. CXCL12 increases cell motility, induces chemotaxis,
increases adhesion to extracellular matrix, and stimulates secre-
tion of MMP-2
[37]
Small cell lung cancer
CXCR4 mRNA and cell-surface protein are detected in cell lines.
CXCL12 induces proliferation, increases adherence and motility,
and induces morphological changes such as ﬁlopodia formation
[98]
Thyroid cancer
HumanthyroidcarcinomacelllinesexpressCXCR4protein,and
CXCR4 is upregulated in primary papillary thyroid carcinomas
compared to normal thyroid tissue. CXCL12 increases prolifera-
tion, inhibits apoptosis, and increases migration and invasion of
human thyroid cancer cells
[99, 100]6 PPAR Research
Table 2: Rosiglitazone downregulation of CXCR4 on HT-29 cells and suppression by PPARγ antagonists. HT-29 cells were treated with
the PPARγ antagonists (I) GW9662 at 1μM or (II) T0070907 at 100nM for 30 minutes before exposure to rosiglitazone (10nM). Cell-
surface CXCR4 protein expression was measured after 48 hours. The data are mean values ± SE (n = 4). The table is taken from [101] with
permission.
Experiment PPARγ antagonist Treatment Decrease due to rosiglitazone (%)
Control Rosiglitazone
I Control 2.53 ±0.14 0.95 ±0.09∗∗∗ 63
GW9662 2.47 ±0.22 2.43 ±0.27 n.s. 2
II Control 1.90 ±0.17 0.81 ±0.11∗∗ 57
T0070907 2.74 ±0.17 3.07 ±0.18 n.s. 0
Signiﬁcant change due to rosiglitazone, ∗∗∗P<. 001; ∗∗P<. 01; n.s.: not signiﬁcant.
in the peripheral blood of breast cancer patients [102], and
CXCR4 expression in breast cancer has been associated with
the presence of individual tumor cells in the bone marrow of
patients [103].
8. CXCR4 IN COLORECTAL CANCER
CXCR4 is abundantly expressed by colorectal carcinoma
cells [104, 105]. The involvement of CXCR4 expression
in colorectal cancer progression was ﬁrst shown by Roos
and colleagues [71]. CT-26 mouse colon carcinoma cells
were transfected with CXCL12 extended with a Lys-Asp-
Glu-Leu (KDEL) sequence. The KDEL receptor functions to
retain resident endoplasmic reticulum (ER) proteins, which
contain a C-terminal KDEL sequence, in the ER. With this
“intrakine approach,” CXCL12-KDEL binds to the KDEL
receptor and is retained in theER, and CXCR4 protein which
binds to CXCL12 is also retained in the ER, preventing its
expression at the cell-surface [71, 106]. This approach was
ﬁrst developed as a strategy to reduce HIV infection [107].
After intrasplenic injection, CXCL12-KDEL-transfected CT-
26 cells, which had reduced cell-surface CXCR4 protein
expression, did not form liver metastases, whereas control
cells did [71]. The incidence of lung metastasis was also
reduced with CXCL12-KDEL-transfected cells, and survival
was increased. Interestingly, unlike Zlotnik’s group, who
had suggested that CXCR4 expression was necessary for the
movement of tumor cells to secondary sites [25], Zeelenberg
and colleagues found that CXCR4 expression was not
required for migration of CT-26 colorectal tumor cells to the
lungs,butratherfortumorexpansionatsecondarysites[71].
Therefore, these authors concluded that CXCR4 is necessary
for the outgrowth of colon cancer micrometastases.
Ottaiano and colleagues found that CXCR4 was over-
expressed in human colorectal carcinoma tissues compared
to normal tissues [40]. Cell-surface CXCR4 protein was
also expressed at high levels on SW620, SW48, and SW480
colorectal carcinoma cells, and at moderate levels on Caco-
2 and LoVo cells. CXCL12 enhanced the chemotaxis of
SW480 cells as well as their adhesion to ﬁbronectin and
collagen type I/III, and both eﬀects were blocked with an
anti-CXCR4 neutralizing antibody. CXCL12 also induced
cytoskeletal changes, proliferation, and ERK1/2 phosphory-
lation in SW480 cells. Similarly, Schimanski and colleagues
found that SW480, SW620, and HT-29 colorectal carcinoma
cells expressed CXCR4 protein, as did colorectal carcinoma
tissue samples [72]. CXCL12 induced the chemotaxis of
SW480 and SW620 cells. Kim and colleagues found that
in patients with colorectal cancer with liver metastases,
higher CXCR4 expression was found on metastatic tissues
compared to the primary tumor [73]. Furthermore, elevated
CXCR4 expression in colorectal cancer is associated with
disease progression and reduced survival [40, 72, 73, 75].
9. THE UTILITY OF CXCR4 AS A MARKER OF
TUMOR PROGRESSION
CXCR4 expression has been associated with disease progres-
sion, increased recurrence, and reduced survival in many
cancer types, as listed in Table 1. As pointed out earlier,
CXCR4 protein expression is detectable in the majority of
cases of DCIS of the breast, whereas CXCR4 levels are very
low in adjacent normal breast epithelium [46]. This suggests
that the acquisition of CXCR4 expression may occur very
early in malignant transformation, suggesting its potential as
a biomarker. As indicated earlier, it has been suggested that
CXCR4expressionmaybeusefulasanindicatorofprognosis
[56, 73].
Although mutations in the CXCR4 gene have not been
reported in the context of cancer, patients with a single
nucleotide polymorphism in the 3  untranslated region
of the CXCL12 gene had reduced incidence of long dis-
tance metastasis of epidermoid non-small cell lung cancer
(NSCLC) [108].
10. PRECLINICAL EFFICACY OF
ANTI-CXCR4 TREATMENTS
Several studies have demonstrated the eﬃcacy of strategies
designed to reduce CXCR4 expression or inhibit its activity
in preclinical models of cancer development and metastasis.
A neutralizing anti-CXCR4 antibody prevented metastasis
of MDA-MB-231 breast cancer cells in mice [25] and in
another study reduced tumor growth after intraperitoneal
(IP) injection of Namalwa non-Hodgkin’s lymphoma cells
[86]. Interestingly, a neutralizing antibody against CXCR4
also inhibited the growth of subcutaneous tumors derived
from pancreatic cancer cells that did not themselves expressC. L. Richard and J. Blay 7
CXCR4, probably because of the ability of the antibody to
block CXCR4 on tumor vasculature [109].
CXCR4 peptide antagonists have also proven eﬀective in
preclinical cancer models. The CXCR4 peptide antagonist
4F-benzoyl-TN14003 inhibited lung metastasis of MDA-
MB-231 breast cancer cells [110], and 4F-benzoyl-TE14011
reduced pulmonary metastasis of B16-BL6 melanoma cells
[111]. Murakami and colleagues assessed the contribution of
CXCR4 to the metastatic process by transducing B16 murine
melanoma cells with CXCR4, followed by IV injection in
syngeneic B57BL/6 mice [112]. CXCR4 expression in this
context led to increased pulmonary metastasis, which was
reduced with the CXCR4 peptide antagonist T22. Liang and
colleagues showed that TN14003 itself, which is a 14-mer
peptide CXCR4 antagonist, inhibited in vitro invasion of
MDA-MB-231 breast cancer cells and lung metastasis after
tail vein injection of these cells, without causing any toxicity
[113].
Small molecule (nonpeptide) inhibitors of CXCR4 have
also been tested in preclinical cancer models. Rubin and col-
leagues showed that the noncompetitive CXCR4 antagonist
AMD3100inhibitedtumorgrowthafterintracranialimplan-
tation of Daoy medulloblastoma cells and U87 glioblastoma
cells [63] and also inhibited peritoneal carcinomatosis and
ascites formation after IP inoculation of NUGC4 human
gastriccarcinomacells[78].Inadiﬀerentapproach,blocking
the mammalian target of rapamycin (mTOR) pathway
downstream of CXCR4 was shown to suppress processes
involved in the peritoneal dissemination of gastric cancer
[114].
Liang and colleagues also showed the preclinical eﬃcacy
of anti-CXCR4 treatments using an RNA-silencing molecu-
lar approach [115]. MDA-MB-231 breast cancer cells trans-
fected with siRNA oligonucleotides to knock down CXCR4
were injected into the tail veins of SCID mice. Mice received
twice-weekly IV injections of siRNA oligonucleotides to
maintain CXCR4 knockdown. The control mice all devel-
oped lung metastases, whereas only one of six mice receiving
CXCR4 siRNA-transfected cells and followup injections with
CXCR4 siRNA developed metastases. Stable knockdown of
CXCR4 expression in 4T1 murine breast carcinoma cells
using short hairpin RNA reduced orthotopic tumor growth
and lung metastasis [49]. Similarly, MDA-MB-231 cells that
had undergone stable knockdown of CXCR4 did not form
tumors or lung metastases after orthotopic injection into
mammary fat pads of SCID mice, whereas CXCR4-positive
cells were tumorigenic [116]. NSCLC 95D lung cancer
cells in which CXCR4 was knocked down using antisense
technology also formed lung metastases in fewer mice after
SC injection compared to CXCR4 positive cells [88]. Finally,
manipulations of CXCR4 expression have become possible
using microRNAs (miRNAs), which are endogenous short
RNAs with the ability to repress the translation of target
mRNAs [117–119]. The approach of expressing a synthetic
miRNA against CXCR4 mRNA to knock down CXCR4
expression has been used successfully in MDA-MB-231
breast cancer cells, HeLa cervical carcinoma cells, and U2-
OS osteosarcoma cells [118, 120, 121]. Reduced CXCR4
expression in the breast cancer model was accompanied by
reduced migration and invasion of the cells in vitro and
fewer lung metastases in vivo [121]. These studies show
the importance of CXCR4 expression in both primary and
secondary tumor growth.
11. CLINICAL ASSESSMENT OF
CXCR4-TARGETED REAGENTS
ThebicyclamcompoundAMD3100wasdevelopedasasmall
moleculeCXCR4antagonist[122].Althoughthiscompound
has not yet been fully assessed in clinical trials to determine
its therapeutic potential in cancer, it has been examined in
small trials in the context of HIV treatment and hematopoi-
etic progenitor cell mobilization [123–128]. One trial with
AMD3100reportedonepatientwiththrombocytopenia,two
patientswithprematureventricularcontractions,andseveral
patients with paresthesias [126]. AMD3100 did not reduce
viral load in HIV patients [122], but did eﬀectively increase
hematopoietic progenitor cell mobilization [124, 125, 127,
128]. However, the mechanisms of action are under debate
and may be unrelated to inhibition of CXCR4 as was ﬁrst
presumed.
12. REGULATION OF CXCR4 EXPRESSION BY
FACTORS WITHIN THE TUMOR
Zeelenberg and colleagues found that CT-26 murine colon
carcinoma cells grown in vitro expressed CXCR4 mRNA, but
cell-surface protein levels were not detectable [71]. When the
same cells were freshly isolated from lung or liver metastases
or from intrasplenic tumors, cell-surface expression was
strongly upregulated. This elevated expression was lost after
2–4daysinculture,indicatingthatitwasnotduetoselection
of a subpopulation of cells with a high CXCR4 expression.
The authors concluded that CXCR4 expression was induced
by the in vivo tumor microenvironment. Although others
have shown that metastatic cells maintain high CXCR4
expression when cultured in vitro [129], and indeed CXCR4
has been suggested as a cancer stem cell biomarker [130],
as discussed below there is substantial evidence indicating
that CXCR4 expression is nevertheless inﬂuenced by the
tumor microenvironment. Additionally, aberrant activation
of signaling pathways within cancer cells, such as those
initiated through HER2, can also contribute to elevated
CXCR4 expression [131].
Multiple features and factors present in the tumor
microenvironment have been shown to regulate CXCR4
expression on tumor cells and other cell types. One such
feature is hypoxia [97, 132]. Solid tumors tend to be
hypoxic due to structural abnormalities in their vasculature
[133]. Staller and colleagues were the ﬁrst to demonstrate
the involvement of hypoxia in the regulation of CXCR4
expression [97]. Their goal was to identify genes regulated
by the von Hippel-Lindau tumor suppressor protein (pVHL)
in renal cell carcinoma cells. pVHL is often inactivated in
renal cell cancer (RCC) leading to constitutive activation
of hypoxia-inducible factor-1 (HIF-1) target genes. In a
microarray analysis, they found that CXCR4 mRNA expres-
sion was suppressed by the reintroduction of functional8 PPAR Research
pVHL into pVHL-deﬁcient A498 RCC cells, an eﬀect that
was due to inactivation of HIF-1. CXCR4 protein was
also downregulated, resulting in reduced migration of RCC
cells towards CXCL12. Hypoxia increased CXCR4 mRNA
expression in HEK-293 human embryonic kidney cells
and primary human proximal renal tubular epithelial cells,
and a hypoxia response element (HRE) was identiﬁed
within the CXCR4 promoter [97]. The authors speculated
that intratumoral hypoxia may lead to increased CXCR4
expression in diverse types of solid tumors, increasing
metastasis to distant organs. Shioppa and colleagues found
that hypoxia increased CXCR4 mRNA and cell-surface
proteinexpressioninseveralcelltypes,includingmonocytes,
human monocyte-derived macrophages, tumor-associated
macrophages, HUVECs, CAOV3 ovarian carcinoma cells,
and MCF-7 breast carcinoma cells, leading to increased
migration towards CXCL12 due to the activation of HIF-1
[132].
The hypoxic environment within tumors also leads
to high extracellular levels of adenosine (adenine-9-β-D-
ribofuranoside), a nucleoside that is involved in energy
metabolism and comprises the core structure for adenine
nucleotides. The concentration of adenosine in the extracel-
lular ﬂuid of solid tumors is about 100-fold that of adjacent
normal tissue [134]. Adenosine concentrations in tumors
reachlevelsthatcanactonanyoffoursubtypesofadenosine-
selective, G-protein-coupled receptors: A1, A2a, A2b, and
A3 [135]. Adenosine receptors of all four known subtypes
are expressed diﬀerentially on diﬀerent cell types within the
tumor,includingstromalcells,endothelialcells,andinﬁltrat-
ing leukocytes. We have shown that through such receptors,
adenosine can have protumor eﬀects directly on cancer
cells and also indirectly via other supporting/inﬁltrating
cells [136–139]. Adenosine also acts through A2a and A2b
adenosine receptors on human colorectal carcinoma cells
to upregulate CXCR4 mRNA expression up to 10-fold, and
selectively increase cell-surface CXCR4 protein up to 3-
fold [31]. This increase in cell-surface CXCR4 enables the
carcinoma cells to migrate toward CXCL12 and enhances
their proliferation in response to CXCL12.
One of the further major factors that allows tumor
expansion is vascular endothelial growth factor (VEGF),
which is also produced in response to hypoxia and which
promotes neovascularisation of the tumor. The angiogenic
eﬀect of VEGF increases the supply of nutrients and blood-
borne growth factors to allow growth of the tumor. There
is signiﬁcant interplay between the roles of VEGF and
CXCR4 in tumor expansion. Concomitan high expression
of CXCR4 and VEGF has been observed in colorectal [74,
75], breast [38], and ovarian [34]c a n c e r s ,a sw e l la si n
glioma [140] and osteosarcoma [91], in each of which it
has been linked to increased angiogenesis, invasion, and/or
metastasis. Clinical studies have shown that although VEGF
and CXCR4 both predispose to lymphatic involvement and
nodal metastasis in colorectal cancer, they work through
diﬀerent regulatory strategies [74]. Their collaborative role
in angiogenesis parallels a similar joint action in noncancer
processes involving neovascularisation (e.g., [141]), and it
has been suggested in the context of tumor angiogenesis that
their actions may be synergistic [34]. It is not surprising that
these two entities are closely linked; VEGF receptors and
CXCR4 have common regulatory pathways. For example,
interference with Notch signalling leads to downregulation
of both VEGF receptor 2 and CXCR4 [142].
The relationship between VEGF and CXCR4 is complex.
Firstly, VEGF can promote CXCR4 pathways. VEGF is
present in high levels in tumors and may upregulate CXCR4
expression on tumor cells, as has been demonstrated in
glioma [143] and breast cancer [144]. In the case of tumor
cells, this upregulation of CXCR4 by VEGF can happen
through an autocrine mechanism [144]. VEGF can also
upregulate CXCR4 on the endothelial cells that may be
involved in angiogenesis during tumor expansion [145, 146].
Conversely, the ability of CXCR4 to signal through
PI3K/Akt and ERK1/2 provides a route through which
VEGF expression may be regulated by CXCR4 [147–149].
Binding of CXCL12 to CXCR4 has been shown to increase
c e l l u l a rs e c r e t i o no fV E G Fi no v a r i a nc a n c e r[ 150], breast
cancer [147], prostate cancer [149, 151], and malignant
glioma [152]. This phenomenon parallels the ability of the
CXCL12/CXCR4 axis to stimulate VEGF secretion in nor-
mal lymphohematopoietic cells [153]. One might therefore
expect a large part of the antitumor activity of CXCR4 antag-
onists to be mediated through reduced secretion of VEGF.
Indeed, interference with the CXCL12-CXCR4 pathway has
been shown to cause downregulation of expression of VEGF
[39].However,blockingtheCXCL12/CXCR4axisinvivocan
inhibit tumor growth and angiogenesis without producing
alterations in VEGF pathways [109].
Other growth factors whose levels are elevated in
tumors may also enhance CXCR4-dependent mechanisms.
Tumors have high levels of tumor necrosis factor-α (TNF-
α), derived primarily from tumor-associated macrophages
(TAMs) [154–156]. TNF-α itself, or macrophages that serve
as a source of TNF-α, are able to increase CXCR4 mRNA and
cell-surface protein expression on ovarian cancer cells [157]
andastrogliomacells[158].Asigniﬁcantcorrelationbetween
TNF-α and CXCR4 expression was found in ovarian cancer
biopsies [157]. The increase in CXCR4 at a cellular level
appears to be due to TNF-α-induced activation of NF-κB
signaling and is associated with enhanced migration towards
CXCL12[157].Therefore,TAMsmaycontributetoincreased
CXCR4 expression on cancer cells via production of TNF-α.
Finally, polypeptide growth factors that are associated
with the extracellular matrix, and indeed components of the
extracellular matrix itself, can upregulate CXCR4 on cancer
cells. Transforming growth factor-β (TGF-β) increases cell-
surfaceCXCR4proteinexpressiononhumanmelanomacells
[35] and we have recently found that FGF-2 upregulates
CXCR4 on human colorectal cancer cells (Bseso B and Blay
J, manuscript in preparation). Furthermore, type-I collagen
and the preparation Matrigel, which is a secreted ECM
rich in laminin [159], also increase levels of CXCR4 on
melanoma cells [35]. Therefore, interactions with matrix
proteinswithintumorsmayalsoincreaseCXCR4expression.C. L. Richard and J. Blay 9
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Figure 1: Production of PGD2 and conversion to its metabolites.
Prostanoids follow an initial common pathway in which arachi-
donic acid is released from membrane phospholipids by phos-
pholipase A2 and then converted to the short-term intermediates
PGG2 and PGH2 by cyclooxygenases. Prostaglandin D synthase
forms PGD2 itself, but subsequent nonenzymatic reactions in
aqueous media lead to the sequential production of prostaglandin
J2 (PGJ2), 9-deoxy-Δ9,Δ12-13,14-dihydro-PGD2 (Δ12-PGJ2), and 15-
deoxy-Δ12,14-PGJ2 (15dPGJ2).
13. THE ROLE OF CYCLOOXYGENASE-2
AND PGE2 IN CANCER
The shift to malignancy in epithelia and indeed the progres-
sion to invasion and metastasis are associated with increased
expression of the enzyme cyclooxygenase-2 (COX-2) [160–
163]. High COX-2 expression is in cancer is often associated
with reduced patient survival [163]. The immediate eﬀect
of high COX-2 expression is increased prostaglandin syn-
thesis, particularly prostaglandin E2 (PGE2)[ 164], which in
experimental models is associated with the production of
vascular loops and arches and evidence of abnormal vessel
function [165], a phenotype consistent with tumor angio-
genesis. Observations of increased expression of angiogenic
regulatory genes, including VEGF, ang-1, and ang-2 are
consistent with this view [166]. Furthermore, nonsteroidal
anti-inﬂammatory drugs (NSAIDs), which inhibit cyclooxy-
genases, reduce both tumor incidence and microvessel
density in COX-2-expressing mice [166] and reduce cancer
progression in preclinical models and clinical trials [167].
Indeed, NSAIDs and COX-2 inhibitors reduce the relative
risk of developing colorectal cancer by 40–50% [167–169].
Tumor-promoting eﬀects of COX-2 overexpression
appear to be due in large part to increased PGE2 production
[170–173]. Associated with the increase in COX-2, there is a
decreased expression of 15-hydroxyprostaglandin dehydro-
genase (15-PGDH), an enzyme involved in the inactivation
of PGE2, in cancer compared to normal tissues [174], as well
as upregulation of cytosolic PLA2 (cPLA2), which increases
the supply of arachidonic acid substrate for COX-2 [175–
177]. In addition to promoting angiogenesis, PGE2 also
stimulates cancer cell proliferation [178, 179], promotes cell
migration [180], and causes transactivation of polypeptide
growth factor receptors [181].
14. OTHER PROSTAGLANDINS IN CANCER
Prostaglandins together with the thromboxanes are classed
as prostanoids, and belong to a larger group of compounds
referred to as eicosanoids [182]. The main prostanoids apart
from PGE2 are prostaglandin F2α (PGF2α), prostaglandin
D2 (PGD2), prostaglandin I2 (PGI2 or prostacyclin), and
thromboxane A2 (TXA2). As well as reﬂecting changes in
COX-2, cPLA2, and inactivating enzymes, the levels of
diﬀerent prostanoids in tumors can be modulated by
altered expression of speciﬁc prostaglandin synthases [183].
Prostaglandins can also be metabolized nonenzymatically
to form a range of products both in the body and in
cell culture. PGD2 can be converted to cyclopentenone
J-series prostaglandins, including prostaglandin J2 (PGJ2),
9-deoxy-Δ9,Δ12-13,14-dihydro-PGD2 (Δ12-PGJ2), and 15-
deoxy-Δ12,14-PGJ2 (15dPGJ2); PGE2 can be converted to
prostaglandin A2 (PGA2)[ 184–186]. The tumor microenvi-
ronment therefore has a rich and varied content of eico-
sanoid mediators.
15. PROSTAGLANDIN EFFECTS ON CANCER CELLS
Although the major focus of attention has been on PGE2,a
range of eicosanoids acts to restrain tumor growth. Indeed
the PGE2 metabolite PGA2 reduces cell number and induces
apoptosis and cell cycle changes in both human breast cancer
cells and human epithelial cervical carcinoma cells [187].
More notably, PGD2 and its series of derivatives have
anticancer eﬀects. PGD2 itself can reduce the growth of
carcinoma cells [188]. However, other studies have shown
that the nonenzymatic breakdown of PGD2 to sequential
metabolites (Figure 1)mayberequiredforgrowthinhibition
and that the latter metabolites are the active eicosanoids
[189–194]. PGD2 therefore can act independently of its
DP receptors by its metabolism through a dehydration
reaction to prostaglandin J2 (PGJ2), Δ12-PGJ2, and then
to 15-deoxy-Δ12,14-prostaglandin J2(15dPGJ2)[ 184]. This
reaction occurs in cell culture media, both in the presence
andabsenceofserum[184,189,195].Therefore,itispossible
that many eﬀects noted in vitro with PGD2 are actually
due to the formation of J-series prostaglandins. Frequent
replacement with fresh medium containing PGD2 in such
circumstances can eliminate the response, while the addition
of the metabolite(s) themselves leads to growth inhibition in
a shorter timeframe than PGD2 itself [189]. Some workers
have proposed that Δ12-PGJ2 is the key metabolite [189];
but in fact all of the successive J-series prostaglandins,
that is, PGJ2, Δ12-PGJ2, and 15dPGJ2, are able to reduce
proliferation and induce apoptosis of cancer cells [190].10 PPAR Research
Furthermore, the end metabolite 15dPGJ2 is active against
many cell types, including colorectal carcinoma cells [191,
192], prostate carcinoma cells [193], and Burkitt lymphoma
cells [194], suggesting that 15dPGJ2 may be the crucial
mediator.
16. THEROLEOF15dPGJ2 ANDITSACTIONONPPARγ
15dPGJ2 is an agonist for the nuclear receptor peroxisome
proliferator-activatedreceptor γ (PPARγ)[196,197],andac-
tivation of PPARγ may account for the growth inhibitory
eﬀects of 15dPGJ2.P P A R γ activation results in its hetero-
dimerization with the retinoid X receptor (RXR), binding
to peroxisome proliferator response elements (PPREs) on
DNA, and subsequent activation of target gene expression
[198]. PPARγ is aberrantly expressed in some cancer types
[199], and in many cases its activation leads to cell death
or diﬀerentiation [191, 200, 201]. This action of 15dPGJ2,
and by extension its precursors PGD2,P G J 2,a n dΔ12-PGJ2,
may underlie the major action of these eicosanoids on
cell growth. For example, 15dPGJ2 reduces the growth of
PC-3 human prostate cancer cells through the activation
of PPARγ [202]. However, in addition to direct growth-
inhibitory eﬀects, 15dPGJ2 may also exert anticancer eﬀects
by reducing expression of protumor proteins. For example,
15dPGJ2 inhibits phorbol ester-induced VEGF and COX-
2 expression in SW620 human colorectal carcinoma cells
[203].
17. 15dPGJ2 CAUSES DOWNREGULATION OF
CXCR4 ON CANCER CELLS
In our studies of the possible eﬀects of these diﬀerent
prostaglandins on CXCR4, we focused upon the expression
of the mature protein and furthermore restricted our
quantitation exclusively to the receptor that is displayed to
theexternalenvironmentatthecellsurface[31].Cell-surface
CXCR4 reﬂects functional receptor that is coupled to cellular
responses [31] rather than the very large intracellular pool of
inaccessible receptor protein [72].
Although PGF2α (to some extent) and PGE2 ( a sw e l la s
its product PGA2) have some ability to modulate CXCR4
levels,byfarthemostpotentprostaglandinsinthisregardare
PGD2 and its derivatives [204]. Prostaglandin D2 and the J-
series prostaglandins used at low micromolar concentrations
cause substantial loss of CXCR4 from the surface of HT-
29 human colorectal carcinoma cells [204]. In particular,
15dPGJ2 completely eliminates cell-surface CXCR4 at a
concentration of 10
−5 M in vitro, and has signiﬁcant eﬀects
after a single dose of 300nM, about 100-fold less than for
PGF2α [204]. The time course of the decline in cell-surface
CXCR4 protein is slow, reaching a maximum only after 48–
72 hours (Figure 2). The concentrations of prostaglandins
that are needed to cause downregulation after a single dose
likely grossly overestimate the steady-state levels that would
cause such a response, as we have found in other studies
with labile metabolites [31, 138]. We estimate that the eﬀect
of 15dPGJ2 on CXCR4 is achievable with concentrations of
15dPGJ2 present in vivo.
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Figure 2: Time course of changes in cell-surface CXCR4 protein
expression on HT-29 cells by PGD2 and its metabolites. HT-29 cells
were treated with vehicle or with 10μMP G D 2 (light gray bars),
10μMP G J 2 (dark gray bars), or 3μM 15dPGJ2 (hatched bars),
and cell-surface CXCR4 protein expression was measured at the
indicated time points. The data shown are expressed relative to the
level of CXCR4 receptor on cells treated with vehicle alone at that
time point. Values have also been corrected for any possible changes
in cell number. The data are mean values ± SE (n = 4). Signiﬁcant
decrease due to prostaglandin, ∗∗P<. 01; ∗P<. 05. The ﬁgure is
taken from [204] with permission.
As can be seen in Figure 2, the response to 15dPGJ2
occurs more rapidly than that to PGJ2, which in turn has
a more rapid onset than PGD2. We further found that
each of these prostaglandins does suppress CXCR4 mRNA
expression and that the eﬀect of 15dPGJ2 again occurs
earlier than that of PGD2 [204]. The diﬀerent relative
kinetics of the downregulation of CXCR4 for the J-series
prostaglandins are consistent with data on the conversion
of PGD2 through to 15dPGJ2 [189] pointing to 15dPGJ2
as the key factor in controlling the levels of functional
CXCR4. PGD2 produces similar downregulation of CXCR4
in other cell types such as the T47D human breast carcinoma
cell line (Richard CL, Blay J, unpublished observations),
suggesting that this may be a common phenomenon. The
downregulation of CXCR4 expression by 15dPGJ2 diﬀers
from 15dPGJ2-mediated downregulation of other proteins,
including cyclin D1 and estrogen receptor α, which has been
shown to occur through protein degradation rather than
through changes in transcription [205].
18. 15dPGJ2 DOWNREGULATES CXCR4
PRIMARILY VIA PPARγ
The main target for 15dPGJ2 i st h en u c l e a rr e c e p t o rP P A R γ
[196, 197]. We found that the ability of 15dPGJ2 to down-
regulate CXCR4 occurred primarily through this pathway.
The eﬀect of 15dPGJ2 was mimicked by PPARγ agonists
such as rosiglitazone (Table 2,[ 206]), and antagonized or
blocked by the PPARγ antagonists GW9662 and T0070907C. L. Richard and J. Blay 11
Primary tumor
e.g. colon or breast cancer
Decreased levels of
receptor (CXCR4) on
tumor cell surface
DNA
PPARγ
CXCR4
Tumor
cell
TZDs 15dPGJ2
Entry into the
vasculature
Metastatic site
e.g. lung, liver, bone
Exit of tumor
cells into tissue
Chemotaxis
Survival
CXCL12 in tissue
Figure 3: How PPARγ downregulation of CXCR4 may act to decrease metastasis. Tumor cells typically have high levels of CXCR4 at their
cellsurface.Duringmetastasis,cancercellsthatﬁndtheirwayintothebloodstreamlodgeintissuesthathavehighconcentrationsofCXCL12
(e.g., lungs, liver, and bone marrow). CXCL12 both encourages the entry of cells into the tissue and promotes growth of the cell population.
Downregulation of CXCR4 by PPARγ activation (endogenous 15dPGJ2 or thiazolidinedione drugs, TZDs) will interfere with this process
and may impede metastasis.
[204], which are irreversible inhibitors of PPARγ [207, 208].
A minor part of the downregulatory activity of 15dPGJ2 was
due to the inhibition of NFκB since the 15dPGJ2 analogue
CAY10410 (9,10-dihydro-15-deoxy-Δ12,14-prostaglandin J2)
[209, 210], which retains the ability to act on PPARγ but
lacks the ability of 15dPGJ2 to inhibit NFκB, was less potent
than 15dPGJ2 [208]. It is the cyclopentenone structure of
15dPGJ2 (not present in CAY10410) that confersan ability to
inhibit NFκB[ 211]. Consistent with a role for this structure,
cyclopentenoneitself(butnotcyclopentaneorcyclopentene)
caused downregulation of CXCR4 [204]. Furthermore, since
PGA2 possesses the cyclopentenone conﬁguration [212],
this explains the ability of PGA2 (and that of PGE2)t o
downregulate CXCR4, although it does not contain the
α,β-unsaturated ketone moiety necessary to activate PPARγ
signaling [210].
The existence of a mechanism of 15dPGJ2-induced
CXCR4 downregulation may, in evolutionary terms, be an
extension of the anti-inﬂammatory eﬀects of 15dPGJ2.L a t e
in the inﬂammation process the prostaglandin proﬁle shifts
from a PGE2-rich state to a PGD2-rich (and therefore
15dPGJ2-rich) state, leading to the resolution of inﬂamma-
tion [213]. Reduced CXCR4 expression may be an additional
mechanism by which 15dPGJ2 attempts the resolution of
inﬂammation.
It is clear that this mechanism is not operative in
the context of metastatic tumors, because CXCR4 levels
are characteristically high (Table 1). Unlike PGE2 which
is present in elevated concentration in tumors [170–173],
15dPGJ2 levels are likely low in tumors compared to normal
tissue. Levels of its precursor PGD2 a r el o wi nt i s s u e so f
familialadenomatouspolyposis,aconditionthatpredisposes
to colorectal cancer [172], and have been negatively corre-
lated with hepatic metastasis in tumor tissues taken from
patients with colorectal cancer [188]. The enzyme involved
in PGD2 synthesis, PGD synthase (PGDS), is decreased
in cerebrospinal ﬂuid of brain cancer patients compared
to patients without disease [214]. There is a contested
report of levels of 15dPGJ2 being decreased during breast
cancer progression, with the lowest levels being detected in
metastatic disease [173]. Finally, mechanisms to sequester
or eliminate 15dPGJ2 may be upregulated in cancer [215,
216]. Overall, it seems that the predominant prostaglandin
w i t h i nt u m o r si sP G E 2, and 15dPGJ2 may not be present
in high levels at all. Thus, 15dPGJ2-dependent suppression
of CXCR4 seems to be a restraint mechanism that is not
operative in a cancer situation.
19. SYNTHETIC PPARγ AGONISTS DOWNREGULATE
CXCR4 ON CANCER CELLS
As indicated above, the PPARγ agonist rosiglitazone also
decreased CXCR4 expression on human colorectal cancer
cells, congruent with an eﬀect of 15dPGJ2 through PPARγ.
This eﬀect was seen at both the mRNA and protein level,
and was more durable than the eﬀect of 15dPGJ2,a si t
w o u l db ee x p e c t e df o ram o r ec h e m i c a l l ys t a b l el i g a n d
[101, 204]. Moreover, we found that other glitazone agents
also downregulate CXCR4, with a rank order of potency
(rosiglitazone > pioglitazone > ciglitazone > troglitazone)
consistent with their potencies for interaction with PPARγ
[206, 217, 218]. Further conﬁrming that these agents were
acting through their expected target, PPARγ, and that this
target is linked to elimination or reduction of CXCR4 at
the cell surface, we showed that the ability of rosiglitazone
to decrease CXCR4 was blocked by the PPARγ antagonists
GW9662 and T0070907 (Table 2), or by shRNA knockdown
of PPARγ expression in the cancer cells [101].
Therefore, rosiglitazone and its analogues act through
PPARγ to cause substantial and persistent suppression of
CXCR4 on cancer cells. Since these agents are the same
chemicals as the thiazolidinedione (TZD) class of drugs
that have been used clinically for the treatment of diabetes
(although recent concerns regarding side eﬀects have limited12 PPAR Research
their utility), it opens up the possibility that we may already
have a means to manipulate CXCR4 levels in cancer. Given
that CXCR4 expression is linked to metastasis, judicious
use of TZDs may allow us an opportunity to inﬂuence the
metastatic process (Figure 3). Recent studies have shown
that a unique population of CXCR4+ stem cells may be
crucial for expansion of tumor cell populations [130]. We
suggest that TZD therapy, by stimulating PPARγ-dependent
downregulation of CXCR4 on cancer cells, may slow the
rate of metastasis and may impact beneﬁcially on disease
progression.
ABBREVIATIONS
CAY10410: 9,10-dihydro-15-deoxy-Δ12,14-prostaglandin J2
CXCL12: CXC chemokine ligand 12
CXCR4: CXC chemokine receptor 4
DCIS: Ductal carcinoma in situ
GW9662: 2-chloro-5-nitro-N-phenylbenzamide
HIF-1: Hypoxia-inducible factor-1
HRE: Hypoxia response element
LESTR: Leukocyte-expressed seven-transmembrane
domain receptor
NF-κB: Nuclear factor-κB
NSAIDs: Nonsteroidal anti-inﬂammatory drugs
NSCLC: Non-small cell lung cancer
PPARγ: Peroxisome proliferator-activated receptor γ
PPRE: Peroxisome proliferator response element
pVHL: Von Hippel-Lindau tumor suppressor protein
RCC: Renal cell cancer
RXR: Retinoid X receptor
SDF-1: Stromal cell-derived factor 1
T0070907: 2-chloro-5-nitro-N-(4-pyridyl)benzamide
TAM: Tumor-associated macrophages
VEGF: Vascular endothelial growth factor
15dPGJ2: 15-deoxy-Δ12,14-PGJ2
15-PGDH: 15-hydroxyprostaglandin dehydrogenase
Δ12-PGJ2: 9-deoxy-Δ9,Δ12-13,14-dihydro-PGD2.
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